Biohaven Pharma (BHVN) Misses Q3 EPS by 4c
Tweet
Share
E-mail
Get Alerts BHVN Hot Sheet
Join SI Premium – FREE
Biohaven Pharma (NYSE: BHVN) reported Q3 EPS of ($1.74), $0.04 worse than the analyst estimate of ($1.70).
For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Downgrades Sands China Ltd. (1928:HK) (SCHYY) to Equalweight
- Goldman Sachs Starts Chagee Holdings (CHA) at Neutral
- Evercore ISI Downgrades TE Connectivity (TEL) to In Line
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
